Compare Organon & Co. Common Stock (OGN) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PepsiCo, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while PepsiCo, Inc. trades at $130.99 (market cap $176.16B). The key difference: PepsiCo, Inc. is far larger — about 48.8× Organon & Co. Common Stock's market cap, and PepsiCo, Inc. pays the higher dividend (4.58%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PepsiCo, Inc. for 108 Days on average.
| OGN | PEP | |
|---|---|---|
Market Cap | $3.61B | $176.16B |
Volume | 1,808,049 | 9,536,018 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $170.44 |
52-Week Low | $5.70 | $123.64 |
Typical Hold Time | 0 Days | 108 Days |
Enterprise Value | $11.03B | $216.88B |
Dividend Yield | 0.58% | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PepsiCo (PEP) trades at $127.28, up 0.44% today, with a bearish technical signal but strong fundamentals including four consecutive quarterly EPS beats. The stock shows a P/E of 16.01 and a net income margin of 11.09%, supported by robust cash flow from operations of $12.09B in 2025. Recent news highlights price adjustments for snacks like Doritos to address consumer pushback on high prices.
The outlook is cautiously optimistic with a consensus price target of $142.38 implying 12% upside, though technical indicators suggest near-term resistance. Risks include competitive pressures and sensitivity to consumer spending trends, but the company's consistent profitability and dividend payments provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
